Your browser doesn't support javascript.
loading
Strategies for successful dose optimization in oncology drug development: a practical guide.
Deng, Qiqi; Zhu, Lili; Weiss, Brendan; Aanur, Praveen; Gao, Lei.
Afiliação
  • Deng Q; Biostatistics and Programming, Moderna Inc., Cambridge, MA, USA.
  • Zhu L; Biostatistics and Programming, Moderna Inc., Cambridge, MA, USA.
  • Weiss B; Clinical Development Oncology, Moderna Inc., Cambridge, MA, USA.
  • Aanur P; Clinical Development Oncology, Moderna Inc., Cambridge, MA, USA.
  • Gao L; Biostatistics and Programming, Moderna Inc., Cambridge, MA, USA.
J Biopharm Stat ; : 1-15, 2024 Aug 11.
Article em En | MEDLINE | ID: mdl-39127994
ABSTRACT
Dose optimization is a critical challenge in drug development. Historically, dose determination in oncology has followed a divergent path from other non-oncology therapeutic areas due to the unique characteristics and requirements in Oncology. However, with the emergence of new drug modalities and mechanisms of drugs in oncology, such as immune therapies, radiopharmaceuticals, targeted therapies, cytostatic agents, and others, the dose-response relationship for efficacy and toxicity could be vastly varied compared to the cytotoxic chemotherapies. The doses below the MTD may demonstrate similar efficacy to the MTD with an improved tolerability profile, resembling what is commonly observed in non-oncology treatments. Hence, alternate strategies for dose optimization are required for new modalities in oncology drug development. This paper delves into the historical evolution of dose finding methods from non-oncology to oncology, highlighting examples and summarizing the underlying drivers of change. Subsequently, a practical framework and guidance are provided to illustrate how dose optimization can be incorporated into various stages of the development program. We provide the following general

recommendations:

1) The objective for phase I is to identify a dose range rather than a single MTD dose for subsequent development to better characterize the safety and tolerability profile within the dose range. 2) At least two doses separable by PK are recommended for dose optimization in phase II. 3) Ideally, dose optimization should be performed before launching the confirmatory study. Nevertheless, innovative designs such as seamless II/III design can be implemented for dose selection and may accelerate the drug development program.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Biopharm Stat Assunto da revista: FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Biopharm Stat Assunto da revista: FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos